HomeATHA • NASDAQ
add
Athira Pharma Inc
$0.32
Makalipas ang Oras ng Trabaho:(0.25%)-0.00080
$0.32
Sarado: Mar 13, 7:34:42 PM GMT-4 · USD · NASDAQ · Disclaimer
Nakaraang pagsara
$0.33
Sakop ng araw
$0.32 - $0.35
Sakop ng taon
$0.30 - $3.67
Market cap
12.39M USD
Average na Volume
196.94K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Mga balita tungkol sa merkado
CoinDesk
42 minuto ang nakalipas
S&P 500 Enters Correction Territory, What Does This Mean For Bitcoin?
1.39%
2.72%
Mga Financial
Income Statement
Kita
Net na kita
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Kita | — | — |
Gastos sa pagpapatakbo | 15.57M | -49.20% |
Net na kita | -15.00M | 45.01% |
Net profit margin | — | — |
Kita sa bawat share | — | — |
EBITDA | -15.32M | 49.59% |
Aktuwal na % ng binabayarang buwis | — | — |
Balance Sheet
Kabuuang asset
Kabuuang sagutin
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Cash at mga panandaliang investment | 51.28M | -65.22% |
Kabuuang asset | 58.78M | -63.32% |
Kabuuang sagutin | 13.94M | -53.63% |
Kabuuang equity | 44.84M | — |
Natitirang share | 39.04M | — |
Presyo para makapag-book | 0.29 | — |
Return on assets | -53.67% | — |
Return on capital | -74.16% | — |
Cash Flow
Net change in cash
| (USD) | Dis 2024info | Y/Y na pagbabago |
|---|---|---|
Net na kita | -15.00M | 45.01% |
Cash mula sa mga operasyon | -26.01M | 1.06% |
Cash mula sa pag-invest | -2.81M | -144.00% |
Cash mula sa financing | 34.00K | -77.63% |
Net change in cash | -28.79M | -45.78% |
Malayang cash flow | -12.30M | 32.48% |
Tungkol
Athira Pharma is a late clinical stage American biopharmaceutical company developing small molecules to restore neuronal health and stop the neurodegeneration brought on by diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.
The company was founded in 2011 and is headquartered in Seattle. Funding that supports the company is from both public and private investment groups including the Alzheimer's Drug Discovery Foundation, Dolby Family Ventures, the State of Washington's Life Sciences Discovery Fund, The W Fund, WRF Capital, and other private investors.
Leen Kawas served as the company's first President and CEO, but resigned in October 2021, after an independent special committee found she "altered images in scientific papers she authored." In 2025, the company paid a $4 million settlement in relation to allegations that the CEO falsified research to secure a federal grant. On October 21, 2021, Mark Litton, Ph.D., M.B.A. became chief executive officer. Wikipedia
Itinatag
2011
Headquarters
Website
Mga Empleyado
26
